Morgan Stanley Acurx Pharmaceuticals, Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Acurx Pharmaceuticals, Inc. stock. As of the latest transaction made, Morgan Stanley holds 106,201 shares of ACXP stock, worth $533,129. This represents 0.0% of its overall portfolio holdings.

Number of Shares

106,201

Previous 106,201 -0.0%

Holding current value

$533,129

Previous $41,000 31.71%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$0.72 - $2.15 $43,200 - $129,000	60,000 Added 129.87%	106,201 $86,000
Q3 2024 May 14, 2025	SELL	$1.83 - $2.62 $366 - $524	-200 Reduced 0.43%	46,201 $87,000
Q3 2024 Nov 14, 2024	SELL	$1.83 - $2.62 $366 - $524	-200 Reduced 0.43%	46,201 $87,000
Q2 2024 May 14, 2025	SELL	$1.64 - $2.79 $98,072 - $166,842	-59,800 Reduced 56.31%	46,401 $104,000
Q2 2024 Oct 17, 2024	BUY	$1.64 - $2.79 $32,800 - $55,800	20,000 Added 75.75%	46,401 $104,000
Q2 2024 Aug 14, 2024	BUY	$1.64 - $2.79 $32,800 - $55,800	20,000 Added 75.75%	46,401 $104,000
Q1 2024 Oct 17, 2024	SELL	$1.94 - $4.81 $38,800 - $96,199	-20,000 Reduced 43.1%	26,401 $64,000
Q1 2024 Aug 16, 2024	BUY	$1.94 - $4.81 $19,788 - $49,061	10,200 Added 62.96%	26,401 $64,000
Q1 2024 May 15, 2024	BUY	$1.94 - $4.81 $19,788 - $49,061	10,200 Added 62.96%	26,401 $64,000
Q4 2023 Aug 16, 2024	SELL	$1.28 - $5.76 $38,656 - $173,952	-30,200 Reduced 65.08%	16,201 $62,000
Q4 2023 Feb 13, 2024	BUY	$1.28 - $5.76 $1,537 - $6,917	1,201 Added 8.01%	16,201 $62,000
Q3 2023 Nov 15, 2023	BUY	$1.41 - $2.55 $21,150 - $38,250	15,000 New	15,000 $22,000
Q1 2022 May 13, 2022	SELL	$3.11 - $4.74 $9 - $14	-3 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$4.02 - $5.64 $12 - $16	3 New	3 $0

Others Institutions Holding ACXP

# of Institutions

Shares Held

2.62M

Call Options Held

62.9K

Put Options Held

56.9K

View Full List

About Acurx Pharmaceuticals, Inc.

Ticker ACXP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,556,600
Market Cap $58M
Description
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...

More about ACXP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account